Pioneering the development
of engineered IgM antibodies
NEWS
PRESENTATIONS & PUBLICATIONS
A Bispecific IgM Antibody Format for Enhanced T cell-Dependent Killing with Minimal Cytokine Release
AACR Virtual Annual Meeting II: June 22-24, 2020
Agonistic Death Receptor 5 (DR5) IgM antibody IGM-8444 induces tumor cell apoptosis in vitro and in vivo and has a favorable in vitro safety profile
AACR Virtual Annual Meeting II: June 22-24, 2020
Defining Clinical Problems and Engineering Solutions in Cancer Immunotherapy
Science Webinar: New horizons in therapeutic antibody discovery: Challenges and opportunities for improvement – June 17, 2020
The Next Era of Cancer Therapeutics: Defining Biologic Problems and Engineering Solutions in Cancer Immunotherapy
PEGS Virtual Interactive Global Summit – June 2-26, 2020
Our Age of Acceleration: Intersections in Immunity, Engineering and Human Health
TIMtalks, MIT – May 30, 2020
IGM-8444 is a potent agonistic Death Receptor 5 (DR5) IgM antibody: Induction of tumor cytotoxicity, combination with chemotherapy and in vitro safety profile
ASCO20 Virtual Scientific Program – May 29-31, 2020
Agonistic Death Receptor 5 (DR5) IgM antibody IGM-8444 induces tumor cell apoptosis in vitro and in vivo and has a favorable in vitro safety profile
AACR Virtual Meeting II – June 22 – 24, 2020 Poster Session: Antibody Technologies – Experimental and Molecular Therapeutics Abstract: 518 / 2, E-Poster: June 22, 2020, 9:00…
A bispecific IgM antibody format for enhanced T cell dependent killing with minimal cytokine release
AACR Virtual Meeting II – June 22 – 24, 2020 Session: Therapeutics Antibodies 4 – Immunology Abstract: 5664 / 25 E-Poster: June 22, 2020, 9:00 AM – 6:00…
IGM-8444 as a potent agonistic Death Receptor 5 (DR5) IgM antibody: Induction of tumor cytotoxicity, combination with chemotherapy and in vitro safety profile.
ASCO20 Virtual Scientific Program – May 29-31, 2020 Poster Session: Developmental Therapeutics–Molecularly Targeted Agents and Tumor Biology Abstract # 3595
Lymphoma cell-killing activity and cytokine release by CD20-directed bispecific IgM antibody-based T-cell engager (IGM-2323)
ASCO20 Virtual Scientific Program – May 29-31, 2020 Session: Developmental Therapeutics–Immunotherapy Abstract # e15007